Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas

Recruiting N/A Interventional Study
Liposarcoma Atypical Lipomatous Tumor
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
158 (estimated)
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria for LPS patients cohort: Men/women older than 18 years old, Surgery for : * Localized WD-LPS and DD-LPS, and/or * WD-LPS or DD-LPS local relapse, and/or * WD-LPS or DD-LPS distant relapse and/or * Deep adipocytic tumor greater than 5 cms, suggestive of atypical lipomatous tumor…
Contacts

Jean-Pierre BLEUSE, MD

0467613102

DRCI-icm105@icm.unicancer.fr

CONTACT